
Adastra: A private pharmaceutical firm specializing in the development of proprietary cancer treatments.
Adastra Pharmaceuticals, founded in San Diego, California, and Princeton, New Jersey, is a privately held company dedicated to the clinical and commercial development of proprietary medicines for cancer treatment. The company's core mission is to innovate and provide effective treatments for the most aggressive forms of cancer, with a strong emphasis on research and development. Adastra's market focus is on high-grade gliomas and other challenging cancer types.
Notable affiliated people include key researchers and industry veterans who drive the company's mission forward. Adastra has achieved significant milestones, including the development and subsequent acquisition of their drug zotiraciclib (ZTR) by Cothera Bioscience. This acquisition underscores Adastra's impact on advancing cancer treatment options and their commitment to improving patient outcomes.

Adhera Therapeutics

Tigris Pharmaceuticals
tigrispharma.com

Adventris Pharmaceuticals

Novita Pharmaceuticals
novita-pharm.com

Whitehawk Therapeutics
aadibio.com

Panacea Pharmaceuticals

Advanced Cancer Therapeutics
Altiris Therapeutics

Acadia Pharmaceuticals
acadia-pharm.com

Camino Pharma
caminopharma.com

Aria Pharmaceuticals

Ascenta Therapeutics

Astria Therapeutics
astriatx.com

EtiraRx
etirarx.com

Thetis Pharmaceuticals
thetispharma.com
Companies similar to Adastra Pharmaceuticals include Adhera Therapeutics, Tigris Pharmaceuticals, Adventris Pharmaceuticals and Novita Pharmaceuticals.
Adastra Pharmaceuticals was founded in 2005.
Adastra Pharmaceuticals' headquarters is located in San Diego, CA, US.
Adastra Pharmaceuticals' most recent funding round was for $3.3M (USD) in November 2016.
As of Nov 15, 2016, Adastra Pharmaceuticals has raised a total of $85M (USD).